http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#Head http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#assertion http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#provenance http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#pubinfo http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#assertion http://purl.obolibrary.org/obo/DOID_7474 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7474 http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00642 http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association http://www.w3.org/2000/01/rdf-schema#label alimta r in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic non squamous nsclc with no egfr or alk genomic tumor aberrations 1 1 in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous non small cell lung cancer nsclc 1 1 as a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous nsclc whose disease has not progressed after four cycles of platinum based first line chemotherapy 1 1 as a single agent for the treatment of patients with recurrent metastatic non squamous nsclc after prior chemotherapy 1 1 limitations of use 1 1 initial treatment in combination with cisplatin of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery 1 2 alimta r in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non squamous non small cell lung cancer nsclc as a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous nsclc whose disease has not progressed after four cycles of platinum based first line chemotherapy as a single agent for the treatment of patients with recurrent metastatic non squamous nsclc after prior chemotherapy limitations of use see clinical studies 14 1 alimta is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00642 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#provenance http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#pubinfo http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#sig http://purl.org/nanopub/x/hasSignature HISWDzXNfZjCDl62GCH7xjMsV83f/2jwcnCaqfaIdshI2kJ4mf1Q8QTATqN/x8yN4EsYAxrs1jbtAAl6BU9taKT+BBRJ8/i2nsBU+HgIYCey4LqYFpK253NU5/Wa1e4qQSnogGyk6vv3se6pIJcCmECTC4KKiVUkOPLCdwJuLQM= http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://purl.org/dc/terms/created 2021-06-12T16:20:36.100+02:00 http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAkrbzE_O52VDGcdelJrkhvpxYydzkcKyW8dQyXZDpRYk https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs